

## Genenta to Participate at Upcoming Investor Conferences

February 24, 2022

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:

[34th Annual ROTH Conference](#), Dana Point, California, U.S.

Date: March 13-15, 2022  
Format: Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development  
Management will also be available for one-on-one meetings

[Maxim Group LLC 2022 Virtual Growth Conference](#)

Date: March 28, 2022  
Format: Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development  
Management will also be available for one-on-one meetings

[HC Wainwright Gene Therapy and Gene Editing Conference](#), virtual

Date: March 30, 2022  
Presenter: Fireside chat with Pierluigi Paracchi, CEO and Carlo Russo, CMO and Head of Development  
Management will also be available for one-on-one meetings

[8th Annual LSX World Congress](#), London, UK and virtual

Date: May 10-11, 2022  
Format: Keynote panel with Pierluigi Paracchi, CEO  
CEO will also be available for one-on-one meetings

Further information on these events may be found on the "News & Events" section of Genenta's Investor website at <https://ir.genenta.com/news-events/events>.

### About Genenta Science

Genenta ([www.genenta.com](http://www.genenta.com)) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a phase 1/2 clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which should induce a durable immune response not restricted to pre-selected tumor antigens nor type and aimed at reaching solid tumors, avoid systemic toxicity, some of the main unresolved challenges in immuno-oncology.

Investor Relations - LifeSci Advisors:  
Mary-Ann Chang, CFA  
+44 7483 28 48 53  
[mchang@lifesciadvisors.com](mailto:mchang@lifesciadvisors.com)

Genenta Media/Investor Contact  
Tiziana Pollio  
+39 3482315143  
[tiziana.pollio@genenta.com](mailto:tiziana.pollio@genenta.com)